Edwards Lifesciences Corporation (EW)

EW · Health Care · United States United States

Edwards Lifesciences Corporation (EW) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.81%. Anyone who holds an ETF containing Edwards Lifesciences Corporation also has an indirect stake in the company.

Data and Charts: Edwards Lifesciences Corporation

Key Data for Edwards Lifesciences Corporation

Held in22 ETFs
Highest weight0.81%
Indices11
SectorHealth Care
CountryUnited States
ISINUS28176E1082
WKN936853

Data note 1

Edwards Lifesciences Corporation Stock Price Chart

The Edwards Lifesciences Corporation chart shows daily closing prices and is set to the current year by default. The stock is up 7.9% year to date and up 10.2% over twelve months. The last recorded close on October 30, 2026, was $92.01, at 84% of the 52-week range.

Price series from our database since Aug 12, 2024, 558 daily values.

Data note 2

Edwards Lifesciences Corporation Stock Performance

Edwards Lifesciences Corporation stock performance
Year to date+7.9%1 year+10.2%
1 month+6.6%3 months+6.9%
Calendar year 2025+15.2%
52W

Data note 3

Measured in euros, Edwards Lifesciences Corporation is up 13.5% year to date and up 13.9% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.

Data note 4

Alysly Data Analysis: Edwards Lifesciences Corporation

What ETF Is Edwards Lifesciences Corporation In?

Edwards Lifesciences Corporation has above-average ETF coverage and is held by 22 of the 104 ETFs we track, which together follow 11 indices. That puts the stock in more ETFs than 85.1% of the 4,341 stocks we track.

Data note 5

What ETF is Edwards Lifesciences Corporation in
ETFIndexWeightper €1,000 in the ETF
XUHL / XUHCMSCI USA Health Care0.81%€8.11
XDWHMSCI World Health Care0.60%€5.99
SPFSMSCI World Health Care0.60%€5.97
2B7KMSCI World SRI0.25%€2.50
XDEWS&P 500 Equal Weight0.21%€2.13
XDEBMSCI World Minimum Volatility0.21%€2.07
SPYL / SPY5S&P 5000.08%€0.83
XD9U / XD9DMSCI USA0.08%€0.82
SXR8S&P 5000.08%€0.80
EUNLMSCI World0.06%€0.60
IUSQMSCI ACWI0.06%€0.60
XDWD / XDWLMSCI World0.06%€0.59
SPYI / SPSAMSCI ACWI IMI0.06%€0.58
SWWDMSCI World0.06%€0.58
SPPWMSCI World0.06%€0.58
WIMIMSCI World IMI0.05%€0.53
SPYYMSCI ACWI0.05%€0.52

Data note 6

The last column shows how much of €1,000 in one of these funds goes to Edwards Lifesciences Corporation, based on each fund's latest holdings list.

US-listed ETFs holding Edwards Lifesciences Corporation (weight per latest SEC filing): IVV 0.08%, SPY 0.08%, VOO 0.08%, VTI 0.07%. These funds are registered in the US; retail investors in the EU usually cannot buy them.

Edwards Lifesciences Corporation Weight in iShares Core MSCI World (EUNL) Since 2019

Sep 30, 2019Oct 30, 2026

In iShares Core MSCI World (EUNL), Edwards Lifesciences Corporation had a weight of 0.11% on Sep 30, 2019 and 0.06% on Oct 30, 2026. The fund tracks the MSCI World. Its share peaked at 0.13% on Dec 31, 2021. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.

Data note 7

What's Inside Your ETF Portfolio and the ETF overlap check show how much Edwards Lifesciences Corporation overlaps with the rest of a portfolio.

Which Tracked Investors Hold Edwards Lifesciences Corporation?

Edwards Lifesciences Corporation is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds Edwards Lifesciences Corporation increased its position.

Tracked investors holding this stock
InvestorSharesValueQuarter
Bridgewater Associates275,279$25Mincreased by 103,356

As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.

Data note 8

What Edwards Lifesciences Corporation Executives and Directors Traded Recently

Trades by executives and directors
DatePersonTypeSharesPrice
Oct 8, 2026Lippis Daniel J. Officer, CVP, TAVRSell (plan)619$85.65

The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.

“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.

Data note 9

Stocks With ETF Exposure Similar to Edwards Lifesciences Corporation

Stocks with ETF exposure similar to Edwards Lifesciences Corporation
StockShared ETFsr1 yearAnnualized volatilityNet marginRevenue growth
Edwards Lifesciences Corporation––+10.2%25.0%17.7%+11.5%
HCA Healthcare Inc22–+1.4%29.0%9.0%+7.1%
Quest Diagnostics Incorporated22–+43.3%22.9%9.0%+11.8%
Incyte Corporation22–+30.0%34.0%25.0%+21.2%
Agilent Technologies21–+22.0%31.4%18.8%+6.7%
IQVIA Holdings Inc21–+23.5%38.6%8.3%+5.9%
Mettler-Toledo International21–+21.6%32.4%21.6%+4.0%
Stryker Corporation21+0.55-20.9%25.8%12.9%+11.2%
Veeva Systems21–+9.8%38.7%28.4%+16.3%

These stocks reach a portfolio through largely the same funds as Edwards Lifesciences Corporation. “Shared ETFs” counts the funds that hold both.

Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.

Data note 10

Fundamental Analysis: Edwards Lifesciences Corporation

Edwards Lifesciences Corporation Key Financials

Revenue$6.1B
Net income$1.1B
Diluted EPS$1.83
Net margin17.7%
Gross margin78.0%
Return on equity10.4%
Equity ratio75.5%
Revenue growth+11.5%

Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).

Revenue and profit by fiscal year
Fiscal yearRevenueNet incomeMargin
FY ended Dec 20235.01.428.0%
FY ended Dec 20245.44.276.7%
FY ended Dec 20256.11.117.7%

Data note 11

Technical Analysis: Edwards Lifesciences Corporation

Edwards Lifesciences Corporation Risk Metrics

Max drawdown-13.2%
Annualized volatility25.0%

Data note 12

Below peak-3.3%
Beta to S&P 5000.55
Correlation to S&P 5000.28

The close on Oct 30, 2026, was 3.3% below the highest close since Aug 12, 2024. That high was reached on Jul 6, 2026. When the S&P 500 rose or fell 1%, Edwards Lifesciences Corporation moved 0.55% on average in the same direction (past 252 trading days). The correlation of 0.28, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Edwards Lifesciences Corporation.

Data note 13

What Edwards Lifesciences Corporation Correlates With

What Edwards Lifesciences Corporation Correlates With
Instrumentr−1 … +1
Stryker Corporation+0.55
IDEXX Laboratories Inc.+0.50
Intuitive Surgical Inc.+0.50
ResMed Inc.+0.45
GE Healthcare Technologies Inc.+0.44
Zimmer Biomet Holdings Inc.+0.44
Hewlett Packard Enterprise Co.-0.31
KAVA-0.31
SOPH-0.30

The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.

Data note 14

Related Content: Edwards Lifesciences Corporation

Latest Investment Analysis: Stocks

Updated